Home> Products> monthly treatment

{ "products": [ { "_id": "695b65af2800555f6696a6cf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cinacalcet 60 mg Tablet", "description": "CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets\nProduct Overview\nCINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body.\nThe 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet.\nUnderstanding How CINASELECT 60 Works\nCINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream.\nWhen you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH).\nBy lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders.\nPrimary Therapeutic Uses\nSecondary Hyperparathyroidism in Chronic Kidney Disease\nThe primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk.\nCINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues.\nHypercalcemia in Parathyroid Carcinoma\nCINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms.\nPrimary Hyperparathyroidism\nFor patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications.\nKey Benefits of CINASELECT 60\nEffective PTH Control\nClinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification.\nImproved Calcium-Phosphorus Balance\nBy reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life.\nReduced Cardiovascular Risk\nElevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients.\nBone Health Preservation\nUncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density.\nAlternative to Surgery\nFor patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky.\nQuality of Life Improvement\nBy controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity.\nConvenient Oral Administration\nCINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients.\nPotential Side Effects and Adverse Reactions\nCommon Side Effects\nPatients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication.\nDiarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue).\nSerious Side Effects Requiring Medical Attention\nHypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities.\nGastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk.\nAdynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels.\nCardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease.\nAllergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported.\nPrecautions and Contraindications\nCINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH.\nPregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment.\nDosage and Administration Guidelines\nCINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided.\nThe typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved.\nDose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response.\nMonitoring Requirements\nPatients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy.\nAdditionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation.\nStorage and Handling\nCINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package.\nConclusion\nCINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications.\nThe benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management.\nHowever, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.", "price": 740.0, "discountamount": 222.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2266, "imageuri": "https://productimages.withfloats.com/actual/695b65ebf30763183f64d4f7.png", "tileimageuri": "https://productimages.withfloats.com/tile/695b65ebf30763183f64d4f7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-05T07:18:07.264Z", "updatedon": "2026-05-01T06:30:26.075Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cinacalcet-60-mg-tablet/2266", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CINASELECT 60", "category": "NEPHROLOGYRANGE", "tags": [ "cinacalcet 60 mg", "cinacalcet mechanism of action.", "cinacalcet uses", "tab cinacalcet.", "cinacalcet dose.", "cinacalcet structure.", "cinacalcet tab.", "calcium and phosphorus levels in the bloodstream.", "parathyroid hormone secretion.", "calcium metabolism disorders.", "chronic kidney disease and parathyroid conditions.", "cinacalcet 60 mg", "cinacalcet 60", "Cinacalcet Tablets 60 mg price in India", "Buy Cinacalcet Tablets 60 mg online", "Cinacalcet 60 mg wholesale price", "Buy Cinacalcet Tablets 60 mg", "Get Cinacalcet Tablets 60 mg at best price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d999cc236afd258ed10348", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nintedanib 100 mg", "description": "NINTEDONE 100 \nNintedanib 100 mg is a cutting-edge oral medication designed to combat progressive lung conditions and certain cancers, offering hope to patients facing debilitating fibrotic diseases. As a small-molecule tyrosine kinase inhibitor, it targets key pathways involved in abnormal cell growth and tissue scarring, making it a vital therapy for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung diseases (PF-ILD). Manufactured to high standards, this formulation delivers precise dosing in a convenient capsule form, ensuring consistent absorption and efficacy for long-term management.​\n\nUses of Nintedanib 100 mg\nNintedanib 100 mg stands out for its approved indications in slowing the decline of lung function in adults with IPF, a chronic and fatal lung disease characterized by progressive scarring of lung tissue. It is also indicated for SSc-ILD, where it helps manage lung fibrosis associated with systemic sclerosis, and PF-ILD, covering other chronic fibrosing lung conditions with a progressive phenotype. Beyond pulmonary fibrosis, Nintedanib has shown utility in oncology, particularly when combined with docetaxel for second-line treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology, inhibiting tumor angiogenesis and growth.​\n\nThis medication addresses the underlying fibrotic processes by restricting fibroblast proliferation and migration, which are central to lung tissue damage. In clinical practice, physicians prescribe Nintedanib 100 mg for patients with confirmed diagnoses via high-resolution CT scans or lung biopsies, often after other treatments fail. Its versatility extends to off-label considerations in other cancers like pancreatic or colorectal, though primary use remains in respiratory fibrosis and lung cancer, providing a targeted approach where traditional therapies fall short.​\n\nKey Benefits of Nintedanib 100 mg\nOne of the primary benefits of Nintedanib 100 mg is its proven ability to reduce the rate of forced vital capacity (FVC) decline, a key measure of lung function, by up to 50% in IPF patients compared to placebo in landmark trials. This translates to slower disease progression, fewer acute exacerbations, and improved quality of life, allowing patients to maintain daily activities longer. The oral administration enhances patient compliance, avoiding the need for infusions or hospital visits.​\n\nSlows Fibrosis Progression: By inhibiting multiple tyrosine kinases, it curbs excessive scar tissue formation in the lungs, preserving respiratory capacity over time.​\n\nAnti-Angiogenic Effects: In cancer settings, it blocks vascular endothelial growth factor receptors (VEGFR), reducing tumor blood supply and metastasis risk.​\n\nBroad-Spectrum Kinase Inhibition: Targets fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others, addressing multifaceted disease pathways.​\n\nManageable Long-Term Use: Clinical data supports sustained benefits with dose adjustments, minimizing hospitalizations for respiratory failure.​\n\nImproved Survival Metrics: In combination therapies for NSCLC, it extends progression-free survival, offering valuable time for patients.​\n\nThese advantages make Nintedanib 100 mg a cornerstone in modern pulmonology and oncology, backed by phase III trials demonstrating statistically significant outcomes in diverse patient populations.​\n\nSide Effects of Nintedanib 100 mg\nWhile effective, Nintedanib 100 mg can cause gastrointestinal side effects as the most common issue, affecting over 60% of users primarily due to its impact on kinase signaling in the gut. Diarrhea often starts within the first two weeks and is typically manageable with dose reduction or antidiarrheal agents like loperamide. Other frequent effects include nausea, vomiting, and decreased appetite, which may lead to weight loss if not addressed.​\n\nMore serious side effects warrant close monitoring:\n\nLiver Enzyme Elevations: Hepatotoxicity occurs in about 10-15% of patients, necessitating monthly liver function tests, especially in those with pre-existing liver conditions.​\n\nCardiovascular Risks: Potential for arterial thromboembolism or hypertension; baseline cardiac evaluation is recommended.​\n\nBleeding Events: Due to VEGF inhibition, minor bleeding like epistaxis is common, but gastrointestinal hemorrhage requires immediate attention.​\n\nRare but Severe: Interstitial lung disease progression (paradoxical worsening), perforations, or severe infections in immunocompromised patients.​\n\nPatients should report persistent diarrhea, abdominal pain, jaundice, or unusual fatigue promptly. Contraindications include pregnancy (category D), active bleeding, or hypersensitivity, with strong recommendations against use in moderate to severe hepatic impairment.​\n\nDosage and Administration Insights\nTypically initiated at 150 mg twice daily for IPF and ILD, Nintedanib 100 mg allows for flexible dosing—starting lower at 100 mg BID if tolerated poorly, with food to reduce GI upset. For NSCLC, it's 200 mg BID with docetaxel cycles. Regular monitoring every 2-3 months adjusts for tolerance, emphasizing adherence to slow disease modification.​\n\nConclusion\nNintedanib 100 mg represents a breakthrough in managing progressive fibrotic lung diseases and select cancers, delivering targeted inhibition of fibrotic and angiogenic pathways for tangible clinical benefits. Its ability to slow FVC decline, enhance patient quality of life, and integrate into combination regimens underscores its value, despite manageable side effects like diarrhea that respond well to supportive care. For those battling IPF, SSc-ILD, or NSCLC, Nintedanib 100 mg offers a proactive defense against relentless progression, empowering longer, more active lives under specialist guidance.​", "price": 795.0, "discountamount": 296.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one capsule", "weight loss", "scar tissue", "key players", "Key Benefits", "lung function", "initial stages", "abdominal pain", "fibrous tissue", "key ingredient", "Bleeding Events", "fibrotic tissue", "daily activities", "tyrosine kinases", "fibrotic process", "Nintedanib 100 mg", "multiple pathways", "active ingredient", "sudden worsenings", "crucial medication", "recommended dosage", "Decreased Appetite", "signaling pathways", "multiple receptors", "overall well-being", "disease progression", "acute exacerbations", "healthcare provider", "Common side effects", "elevated liver enzymes", "Gastrointestinal Issues", "other fibrotic diseases", "Liver Enzyme Elevations", "tyrosine kinase inhibitor", "progressive lung conditions", "other fibrotic lung diseases", "idiopathic pulmonary fibrosis", "potent pharmaceutical formulation", "fibroblast growth factor receptor", "platelet-derived growth factor receptor", "vascular endothelial growth factor receptor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1971, "imageuri": "https://productimages.withfloats.com/actual/66d999d4f2036c2969cdeca8.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d999d4f2036c2969cdeca8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-05T11:45:16.665Z", "updatedon": "2026-03-14T06:46:45.85Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//nintedanib-100-mg/1971", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NINTEDONE 100 ", "category": "NEPHROLOGYRANGE", "tags": [ "lung conditions and certain cancers", "Nintedanib 100 mg", "pulmonary fibrosis (IPF)", "fibrosis and lung cancer", "nintedanib 100 mg", "nintedanib capsules 100 mg", "nintedanib 100 mg capsules", "nintedanib 100 mg medicine", "nintedanib 100 mg tablet uses", "what is nintedanib 100 mg used for", "how nintedanib 100 mg works", "nintedanib 100 mg uses and benefits", "nintedanib 100 mg for lung disease", "nintedanib 100 mg for pulmonary fibrosis", "nintedanib 100 mg for idiopathic pulmonary fibrosis", "nintedanib 100 mg for interstitial lung disease", "nintedanib capsules for chronic lung disease", "nintedanib 100 mg price in india", "nintedanib 100 mg capsules price", "buy nintedanib 100 mg online", "nintedanib 100 mg supplier india", "nintedanib 100 mg manufacturer", "when should nintedanib 100 mg be taken", "who should take nintedanib 100 mg", "can nintedanib slow lung fibrosis", "how long to take nintedanib 100 mg", "does nintedanib cure pulmonary fibrosis" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66694f6bca84cd189c25ac3e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pirfenidone 400mg", "description": "PIRFENOID 400 is a pharmaceutical formulation containing Pirfenidone 400mg as its active ingredient. This medication represents a significant advancement in the treatment of idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring of lung tissue. PIRFENOID 400 belongs to a class of medications known as antifibrotic agents, designed to slow the progression of lung fibrosis and help patients maintain their quality of life.\nIdiopathic pulmonary fibrosis is a chronic, progressive condition where the lung tissue becomes thick and stiff over time, making it increasingly difficult for patients to breathe. PIRFENOID 400 works at the cellular level to address this scarring process, offering hope to those diagnosed with this challenging condition.\nUnderstanding How PIRFENOID 400 Works\nThe active ingredient in PIRFENOID 400, Pirfenidone, operates through multiple mechanisms to combat pulmonary fibrosis. While the exact mechanism is not completely understood, research suggests that Pirfenidone exhibits both antifibrotic and anti-inflammatory properties. It works by reducing the production of growth factors and procollagens, which are substances involved in the formation of scar tissue in the lungs.\nBy interfering with the fibrotic process, PIRFENOID 400 helps slow down the rate at which lung tissue becomes scarred and damaged. This intervention is crucial because once lung tissue becomes severely scarred, the damage is generally irreversible. The medication doesn't cure IPF, but it can significantly slow its progression, allowing patients to maintain better lung function for longer periods.\nPrimary Uses and Indications\nPIRFENOID 400 is primarily prescribed for the treatment of mild to moderate idiopathic pulmonary fibrosis. Healthcare providers recommend this medication for patients who have been diagnosed with IPF through comprehensive testing, including high-resolution CT scans, pulmonary function tests, and sometimes lung biopsies.\nThe medication is most effective when started early in the disease process, before extensive lung damage has occurred. It is intended for long-term use as part of a comprehensive treatment plan that may also include pulmonary rehabilitation, oxygen therapy, and other supportive measures.\nKey Benefits of PIRFENOID 400\nSlowing Disease Progression\nThe most significant benefit of PIRFENOID 400 is its ability to slow the progression of idiopathic pulmonary fibrosis. Clinical studies have demonstrated that patients taking Pirfenidone experience a reduced decline in lung function compared to those not receiving treatment. This means patients can maintain their breathing capacity and overall lung health for extended periods.\nImproved Quality of Life\nBy slowing disease progression, PIRFENOID 400 helps patients maintain their ability to perform daily activities. Patients often report being able to continue working, engaging in social activities, and maintaining independence longer than they might without treatment. This preservation of quality of life is invaluable for both patients and their families.\nReduced Risk of Acute Exacerbations\nResearch indicates that PIRFENOID 400 may help reduce the risk of acute exacerbations of IPF, which are sudden worsening episodes that can be life-threatening. By stabilizing the disease, the medication provides patients with more predictable disease management and fewer emergency situations.\nExtended Survival Rates\nStudies have shown that treatment with Pirfenidone may be associated with improved survival rates in IPF patients. While IPF remains a serious condition, PIRFENOID 400 offers patients additional time and better overall outcomes.\nWell-Established Safety Profile\nPIRFENOID 400 has been extensively studied in clinical trials involving thousands of patients worldwide. This extensive research has established a well-understood safety profile, allowing healthcare providers to effectively manage and monitor patients on this therapy.\nDosage and Administration\nPIRFENOID 400 is typically administered orally with food to reduce the likelihood of gastrointestinal side effects. The usual recommended dosage involves a gradual titration period where the dose is slowly increased over the initial weeks of treatment to help the body adjust to the medication. Patients should always follow their healthcare provider's specific dosing instructions and never adjust their dose without medical guidance.\nPotential Side Effects\nLike all medications, PIRFENOID 400 can cause side effects, though not everyone experiences them. Understanding these potential effects helps patients and healthcare providers monitor treatment effectively.\nCommon Side Effects\nThe most frequently reported side effects include nausea, loss of appetite, stomach upset, diarrhea, and indigestion. These gastrointestinal effects are often most noticeable when starting treatment but may improve over time. Taking the medication with food can help minimize these symptoms.\nSkin-related side effects are also common, including photosensitivity (increased sensitivity to sunlight), rash, and dry skin. Patients taking PIRFENOID 400 should use broad-spectrum sunscreen and protective clothing when exposed to sunlight.\nFatigue and dizziness are reported by some patients, particularly during the initial treatment period. These effects may impact daily activities and should be discussed with a healthcare provider if they persist or worsen.\nLess Common but Serious Side Effects\nElevated liver enzymes have been observed in some patients taking Pirfenidone, which is why regular liver function monitoring is essential during treatment. Most cases are mild and reversible with dose adjustment or temporary discontinuation.\nSome patients may experience significant weight loss, which requires nutritional monitoring and support. Rare cases of angioedema (severe swelling) and severe allergic reactions have been reported and require immediate medical attention.\nManaging Side Effects\nMost side effects can be effectively managed through dose adjustments, symptomatic treatment, or temporary interruption of therapy. Open communication with healthcare providers is essential for optimizing treatment while minimizing adverse effects.\nImportant Precautions and Monitoring\nPatients taking PIRFENOID 400 require regular monitoring, including liver function tests, typically performed monthly for the first six months and then periodically thereafter. Sun protection measures are crucial, including use of SPF 50+ sunscreen, protective clothing, and avoiding peak sun hours.\nWomen of childbearing potential should use effective contraception, as the safety of Pirfenidone during pregnancy has not been established. Patients should inform their healthcare provider of all other medications they are taking, as drug interactions may occur.\nSmoking can reduce the effectiveness of PIRFENOID 400, and patients are strongly encouraged to quit smoking as part of their comprehensive IPF management strategy.\nConclusion\nPIRFENOID 400 represents a valuable therapeutic option for patients diagnosed with idiopathic pulmonary fibrosis. By slowing disease progression, reducing the decline in lung function, and potentially improving survival outcomes, this medication offers meaningful benefits to those facing this challenging condition. While side effects can occur, they are generally manageable with appropriate monitoring and medical support.\n\n\n\n\n\n\n\n", "price": 439.0, "discountamount": 132.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "IPF", "rash", "drug", "400mg", "ORDER", "Email", "801mg", "nausea", "doctor", "fatigue", "product", "guidance", "WhatsApp", "PIRFENOID", "medication", "Pirfenidone", "information", "sterispharma", "inflammation", "Side effects", "usual dosage", "sterisonline", "lung scarring", "optimal results", "disease progression", "idiopathic pulmonary fibrosis" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1774, "imageuri": "https://productimages.withfloats.com/actual/66694f6d5e294343790b2279.png", "tileimageuri": "https://productimages.withfloats.com/tile/66694f6d5e294343790b2279.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-12T07:34:03.278Z", "updatedon": "2026-05-20T07:10:29.655Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//pirfenidone-400mg/1774", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PIRFENOID 400", "category": "RESPIRTORYRANGE", "tags": [ "Pirfenidone (400mg) price", "pirfenidone 400 mg uses in hindi", "pirfenidone 400 mg side effects in hindi", "pirfenidone (400mg) benefits", "pirfenidone 400 mg tablet", "pirfenidone 400 mg tablets", "pirfenidone 400 mg price", "pirfenidone 400 mg dosage", "pirfenidone 400 mg composition", "buy pirfenidone 400 mg tablet", "pirfenidone 400 mg tablet manufacturer", "pirfenidone 400 mg tablet supplier", "pirfenidone 400 mg tablet wholesale", "pirfenidone 400 mg for pulmonary fibrosis", "pirfenidone 400 mg treatment benefits", "pirfenidone 400 mg tablets in India", "pirfenidone 400 mg supplier India", "Buy Pirfenidone 400mg online", "Order Pirfenidone 400mg online India", "Pirfenidone 400mg wholesale price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6666d20b54b2801048924817", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "IBANDZONIC 150 ", "description": "IBANDZONIC 150 \nIbandronate Sodium (150mg)\nIntroduction\nIBANDZONIC 150 contains Ibandronate Sodium (150mg), a potent bisphosphonate medication used to prevent and treat osteoporosis in postmenopausal women. Osteoporosis is a condition characterized by weakened bones and an increased risk of fractures. Ibandronate Sodium works by inhibiting bone resorption, leading to increased bone mineral density and reduced fracture risk.\n\nKey Ingredient and Its Benefits\nIbandronate Sodium (150mg)\nInhibits Bone Resorption: Ibandronate Sodium is a bisphosphonate that slows down or prevents bone resorption, a process where bone tissue is broken down and minerals are released into the blood. This helps to maintain or increase bone density.\nIncreases Bone Density: By inhibiting bone resorption, Ibandronate Sodium helps increase bone mineral density, making bones stronger and less prone to fractures.\nReduces Fracture Risk: Clinical studies have shown that Ibandronate Sodium significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis.\nBenefits of IBANDZONIC 150\nPrevents and Treats Osteoporosis: IBANDZONIC 150 is effective in both the prevention and treatment of osteoporosis, helping to maintain bone health in postmenopausal women.\nIncreases Bone Strength: By increasing bone mineral density, IBANDZONIC 150 strengthens bones, reducing the risk of fractures.\nConvenient Monthly Dosing: The once-monthly dosing regimen of IBANDZONIC 150 offers convenience and improves adherence compared to more frequent dosing schedules.\nProven Efficacy: Clinical trials have demonstrated the efficacy of Ibandronate Sodium in reducing fracture risk and improving bone density.\nDosage and Administration\nDosage\nRecommended Dosage: The typical dosage of IBANDZONIC 150 for the prevention and treatment of osteoporosis is one tablet taken once a month. The exact dosage and duration of treatment should be determined by a healthcare provider based on individual patient needs.\nAdministration\nOral Use: Take the tablet whole with a full glass of plain water (6-8 ounces) on an empty stomach. Avoid lying down for at least 60 minutes after taking the medication to prevent esophageal irritation.\nTiming: Take IBANDZONIC 150 at least 60 minutes before consuming any food, beverages (other than plain water), or other medications or supplements.\nConsistency: For optimal results, take the medication on the same date each month to maintain a consistent dosing schedule.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \nBUY NOW\nhttps://www.sterisonline.com/product/ibandzonic-150-134171", "price": 221.0, "discountamount": 66.3, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "BUY", "food", "bones", "blood", "150mg", "EMAIL", "Timing", "Treats", "process", "Inhibits", "weakened", "duration", "Prevents", "minerals", "Oral Use", "Benefits", "beverages", "condition", "same date", "increased", "adherence", "treatment", "full glass", "IBANDZONIC", "prevention", "one tablet", "60 minutes", "supplements", "bone health", "bone tissue", "convenience", "Consistency", "information", "plain water", "osteoporosis", "Introduction", "exact dosage", "sterisonline", "sterispharma", "bone density", "CALL/WHATSAPP", "Bone Strength", "fracture risk", "empty stomach", "typical dosage", "Key Ingredient", "Clinical trials", "Proven Efficacy", "bone resorption", "optimal results", "Clinical studies", "other medications", "Ibandronate Sodium", "Recommended Dosage", "healthcare provider", "postmenopausal women", "bone mineral density", "Administration Dosage", "esophageal irritation", "monthly dosing regimen", "non-vertebral fractures", "individual patient needs", "frequent dosing schedules", "Convenient Monthly Dosing", "consistent dosing schedule", "potent bisphosphonate medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1664, "imageuri": "https://productimages.withfloats.com/actual/6666d20e0b4fc76a999ab2ab.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6666d20e0b4fc76a999ab2ab.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-10T10:14:35.368Z", "updatedon": "2026-03-14T07:08:59.352Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ibandzonic-150-/1664", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IBANDZONIC 150 ", "category": "ORTHOLOGYRANG", "tags": [ "IBANDZONIC 150 mg", "Ibandronate Sodium (150mg)", "", "ibandronate 150 mg tablet uses", "", "ibandronate 150 mg tablet price", "", "ibandronate 150 mg side effects", "", "ibandronate sodium injection" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e3b87247ae19c482b97c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Enzalutamide 40mg", "description": "Enzalutamide 40 mg capsules represent a breakthrough in targeted therapy for advanced prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). This second-generation androgen receptor inhibitor works by disrupting multiple steps in the androgen signaling pathway, offering patients a chance to slow disease progression, reduce tumor burden, and extend survival even after other treatments fail. Administered as a once-daily oral capsule, enzalutamide 40 mg provides four capsules per day (total 160 mg), making it convenient for long-term use in clinical settings where hormone therapy alone proves insufficient.​\n\nPatients often turn to enzalutamide when facing rising PSA levels despite androgen deprivation therapy (ADT), experiencing bone pain, or dealing with cancer spread to lymph nodes or distant sites. Its high affinity for androgen receptors—5-8 times stronger than first-generation antiandrogens like bicalutamide—ensures potent blockade without agonist activity, translating to real-world benefits like delayed chemotherapy needs and improved quality of life during treatment.​\n\nProduct Use and Indications\nEnzalutamide 40 mg primarily treats metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel or progressing despite ADT. The FDA and EMA approvals extend to non-metastatic CRPC (nmCRPC) with high-risk biochemical recurrence and metastatic castration-sensitive prostate cancer (mCSPC) alongside ADT, based on landmark trials like AFFIRM, PREVAIL, PROSPER, and ARCHES.​\n\nKey uses include:\n\nSlowing tumor growth in hormone-refractory stages by inhibiting androgen-driven proliferation.\n\nReducing skeletal-related events like fractures or spinal cord compression in bone metastases.\n\nDelaying progression to chemotherapy in pre-chemotherapy mCRPC, with PREVAIL showing 17-month median radiographic progression-free survival (rPFS) versus 4 months for placebo.​\n\nIn mCSPC, ARCHES trial data demonstrated 61% risk reduction in progression or death when combined with ADT. Clinicians monitor PSA response (≥50% decline in 70-80% of patients) and imaging every 3 months to assess efficacy.​\n\nMechanism of Action\nEnzalutamide 40 mg exerts a threefold blockade on androgen receptor (AR) signaling: it competitively inhibits androgen binding to AR (with affinity rivaling dihydrotestosterone), prevents nuclear translocation of the ligand-receptor complex, and disrupts DNA binding and coactivator recruitment at androgen response elements. This comprehensive inhibition downregulates oncogenes like TMPRSS2-ERG fusion genes common in prostate cancer, inducing apoptosis and halting cell proliferation without lowering systemic testosterone levels.​\n\nUnlike earlier antiandrogens, enzalutamide avoids partial agonist effects, ensuring pure antagonism even in AR-overexpressing tumors. Its active metabolite, N-desmethyl enzalutamide (via CYP2C8), contributes 30% to activity, with steady-state levels achieved in 4 weeks.​\n\nKey Benefits\nExtended Progression-Free Survival: In PREVAIL (pre-chemo mCRPC), median overall survival reached 32.4 months versus 30.2 for placebo; PROSPER (nmCRPC) delayed metastasis by 22 months.​\n\nPSA Response and Tumor Shrinkage: 78% PSA90 response rate; radiographic responses in 29% with measurable disease.​\n\nQuality of Life Preservation: Delays pain progression (hazard ratio 0.40) and chemotherapy (by 17 months), maintaining daily function.​\n\nBone Protection: Reduces fractures by 30% in high-risk patients via AR inhibition in osteoblasts.​\n\nCombination Synergy: Enhances ADT efficacy in mCSPC, cutting death risk by 33% per ARCHES.​\n\nThese benefits position enzalutamide 40 mg as a cornerstone in modern prostate cancer protocols, especially for fit patients tolerating oral therapy.​\n\nSide Effects\nEnzalutamide 40 mg carries a manageable profile, with most effects dose-related and reversible upon discontinuation.\n\nCommon Side Effects\nFatigue/Asthenia (34-50%): Often mild, peaking in first months; rest and nutrition help.\n\nArthralgia/Myalgia (14-21%): Joint/muscle pain managed with NSAIDs.\n\nHot Flashes (20%): Androgen blockade mimic; hydration aids.\n\nHeadache/Dizziness (12-19%): Transient; avoid driving if severe.\n\nHypertension (6-13%): Monitor BP monthly; antihypertensives as needed.\n\nGI Issues (diarrhea 12%, nausea 11%): Antiemetics support compliance.​\n\nSerious Side Effects\nSeizures (0.9%): Highest risk in epileptics or brain mets; EEG baseline, avoid triggers.\n\nPosterior Reversible Encephalopathy (PRES): Rare (<0.1%); headache, confusion—MRI confirms.\n\nFalls/Fractures (15% increased risk): Due to weakness/falls; DEXA scans recommended.\n\nCardiac Events (2-5%): MI/arrhythmias; ECG monitoring in CVD history.\n\nHepatic Injury (1%): ALT/AST elevation; monthly labs first 3 months.​\n\nDiscontinuation occurs in 8-10%; supportive care mitigates most.​\n\nDosage and Administration\nStandard dose: 160 mg (four 40 mg capsules) once daily, with or without food. Swallow intact; no crushing. Adjust for CYP2A4 inducers (e.g., rifampin—increase to 240 mg) or strong inhibitors (reduce to 80 mg). Continue until progression/toxicity; no dose interruptions beyond 28 days without reassessment.​\n\nPrecautions and Monitoring\nContraindicated in pregnancy (teratogenic; absolute contraception for men/ partners). Screen for seizure history; CYP2C8/3A4 interactions (e.g., ketoconazole). Baseline LFTs, PSA, testosterone; imaging q8-12 weeks. Elderly (>75) monitor falls.​\nConclusion\nEnzalutamide 40 mg stands as a transformative therapy, empowering prostate cancer patients with prolonged control over aggressive disease through precise AR inhibition. Balancing robust efficacy—evidenced by landmark trials delaying metastasis and death—with proactive side effect management, it enhances survival and daily living. Patients achieve meaningful milestones, from family events to travel, underscoring its role in personalized oncology. Consult oncologists for integration into care plans, ensuring optimal outcomes in this challenging journey.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\n\n\n\n\n\n\n\n\n", "price": 10781.0, "discountamount": 3235.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "Email", "doctor", "product", "fatigue", "WhatsApp", "treatment", "schedules", "ENZULAMIDE", "monitoring", "hot flashes", "information", "sterisonline", "hypertension", "sterispharma", "prostate cancer", "Enzalutamide 40mg", "prescribed dosages", "androgen receptors", "cancer cell growth", "Common side effects", "comprehensive guidance" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1527, "imageuri": "https://productimages.withfloats.com/actual/667d2a356c582d228f45a098.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d2a356c582d228f45a098.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:40:56.587Z", "updatedon": "2026-03-16T08:18:18.117Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//enzalutamide-40mg/1527", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ENZULAMIDE 40", "category": "Oncology", "tags": [ "enzalutamide 40 mg side effects", "enzalutamide 40 mg brands in india", "enzalutamide 40 mg uses in hindi", "enzalutamide 40 mg dosage", "advanced prostate cancer", "prostate cancer", "metastatic castration-resistant prostate cancer", "enzalutamide 40mg tablets", "enzalutamide 40 mg capsule", "enzalutamide 40mg uses", "enzalutamide 40mg dosage", "enzalutamide 40mg price in india", "enzalutamide 40mg composition", "enzalutamide 40mg working mechanism", "enzalutamide 40mg side effects", "enzalutamide 40mg benefits", "enzalutamide 40mg drug information", "enzalutamide 40mg therapy details", "enzalutamide 40mg oral capsule", "enzalutamide 40mg treatment option", "enzalutamide 40mg pharmaceutical uses", "enzalutamide 40mg branded tablets", "enzalutamide 40mg generic medicine", "enzalutamide 40mg manufacturer in india", "what is enzalutamide 40mg used for", "how enzalutamide 40mg works", "is enzalutamide 40mg safe", "enzalutamide 40mg tablet information", "enzalutamide 40mg dosage guidelines" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661a57d8da3a81d5c6a17dd", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Mycophenolate mofetil 500mg", "description": "MYCOPLASM M 500\nMycophenolate mofetil (500mg)\nMycoplasm M 500 is a medication containing Mycophenolate Mofetil in a 500mg dose. Mycophenolate Mofetil is an immunosuppressive drug used to prevent rejection in organ transplantation, particularly kidney, heart, and liver transplants. It works by inhibiting the proliferation of T and B lymphocytes, which are involved in the immune response that leads to rejection.\n\nThis medication is typically prescribed in combination with other immunosuppressants as part of a comprehensive transplant treatment regimen. It is important to take Mycoplasm M 500 exactly as prescribed by your healthcare provider to ensure optimal therapeutic outcomes and to minimize the risk of rejection or other complications.\n\nCommon side effects of Mycophenolate Mofetil may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. It can also increase the risk of infections due to its immunosuppressive effects. Patients should be monitored regularly by their healthcare provider while taking this medication to assess for any potential adverse effects and to adjust the dosage as needed.\n\nMycoplasm M 500 should not be used in pregnant women or those planning to become pregnant without consulting a healthcare professional, as it can cause harm to the developing fetus. Additionally, it may interact with other medications, so it is important to inform your doctor about all the medications you are currently taking before starting Mycoplasm M 500 therapy.For further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \n\n\n\n\nMycophenolate mofetil 500 mg stands as a cornerstone in modern immunosuppressive therapy, primarily designed to prevent organ transplant rejection in kidney, heart, and liver recipients. As a prodrug, it rapidly converts to its active form, mycophenolic acid (MPA), which selectively targets the proliferation of T and B lymphocytes—key players in immune responses that can attack transplanted organs. This medication, available in convenient 500 mg tablets, offers reliable protection against acute rejection episodes, making it an essential component in post-transplant regimens worldwide.​\n\nProduct Uses\nMycophenolate mofetil 500 mg finds its primary application in solid organ transplantation, where it helps maintain long-term graft survival. For kidney transplant patients, it is typically administered alongside corticosteroids and calcineurin inhibitors like cyclosporine or tacrolimus to suppress the immune system's overreaction to the new organ. In heart and liver transplants, it plays a similar role, reducing the incidence of rejection by inhibiting antibody production and cell-mediated immunity.​\n\nBeyond transplants, healthcare providers increasingly use mycophenolate mofetil 500 mg for various autoimmune conditions. It effectively manages lupus nephritis by curbing inflammation in the kidneys, showing superior efficacy over traditional therapies in preserving renal function. Rheumatoid arthritis patients benefit from its ability to dampen joint inflammation, while those with dermatomyositis or scleroderma experience reduced skin and muscle involvement. Off-label, it treats inflammatory bowel diseases like Crohn's disease and even certain skin disorders such as pemphigus vulgaris, where immune-mediated blistering threatens quality of life.​\n\nKey Benefits\nThe therapeutic advantages of mycophenolate mofetil 500 mg extend far beyond basic immunosuppression, offering patients enhanced outcomes and improved daily living.\n\nSuperior Graft Protection: Clinical data highlight reduced acute rejection rates by up to 50% when combined with standard regimens, leading to better long-term organ function and survival.​\n\nSelective Lymphocyte Targeting: By depleting guanosine nucleotides in T and B cells via inosine monophosphate dehydrogenase (IMPDH) inhibition, it spares other cell types, minimizing broad toxicity seen with older immunosuppressants.​\n\nAnti-Inflammatory Effects: MPA inhibits adhesion molecule glycosylation, preventing lymphocyte recruitment to inflamed sites, which alleviates symptoms in autoimmune flares.​\n\nOral Convenience: The 500 mg formulation allows flexible dosing—typically 1 gram twice daily—without the need for injections, improving patient adherence.​\n\nVersatility Across Conditions: Proven efficacy in lupus, vasculitis, and myositis expands its utility, often allowing steroid dose reduction and fewer relapses.​\n\nCardiovascular and Anticancer Potential: Emerging evidence suggests it delays graft atherosclerosis by reducing lipid oxidation and may hinder tumor progression in certain malignancies due to its impact on nucleotide synthesis.​\n\nThese benefits translate to fewer hospital readmissions, better quality of life, and cost savings in long-term care for transplant and autoimmune patients.​\n\nSide Effects\nWhile mycophenolate mofetil 500 mg provides robust immunosuppression, it carries risks typical of this drug class, necessitating vigilant monitoring.\n\nCommon side effects affect the gastrointestinal tract most prominently, with nausea, vomiting, diarrhea, and abdominal pain occurring in over 30% of users. These often improve with dose adjustments or enteric-coated alternatives, but hydration and antiemetics help manage them effectively.​\n\nHematologic issues like leukopenia, anemia, and thrombocytopenia arise due to bone marrow suppression, requiring regular complete blood counts—weekly initially, then monthly. Infections pose a significant threat, as suppressed immunity increases susceptibility to viral (e.g., CMV), bacterial, and fungal pathogens; prophylactic antivirals are standard.​\n\nLess frequent but notable effects include hypertension, tremor, insomnia, and elevated liver enzymes. Women face heightened risks of congenital malformations if used during pregnancy, mandating effective contraception and pregnancy testing. Rare severe reactions encompass progressive multifocal leukoencephalopathy (PML) from JC virus reactivation and hypersensitivity syndromes.​\n\nDosage and Administration Notes\nStandard dosing for renal transplants involves 1 gram (two 500 mg tablets) twice daily, starting within 72 hours post-surgery, with adjustments for renal impairment. Hepatic transplant patients may require higher initial doses due to metabolism differences. Always take on an empty stomach with water to optimize absorption, avoiding antacids that bind MPA.​\n\nPrecautions and Interactions\nPatients must avoid live vaccines, report fevers promptly, and undergo TB screening pre-treatment. Drug interactions with azathioprine, cholestyramine, or rifampin can alter levels, so pharmacists review regimens closely. Regular monitoring of MPA blood levels ensures therapeutic efficacy without toxicity.​\n\nConclusion\nMycophenolate mofetil 500 mg emerges as a transformative immunosuppressive agent, safeguarding transplanted organs and taming autoimmune storms with its precise mechanism of lymphocyte suppression and anti-inflammatory prowess. By delivering key benefits like reduced rejection, versatile applications, and manageable administration, it empowers patients to reclaim normalcy post-transplant or amid chronic illness. Despite potential side effects, proactive monitoring and personalized dosing mitigate risks, underscoring its value in contemporary medicine. For those navigating transplant recovery or autoimmune challenges, this medication offers hope and stability, backed by decades of clinical validation.\n\n", "price": 775.0, "discountamount": 256.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "part", "Call", "harm", "risk", "Email", "heart", "ORDER", "nausea", "kidney", "dosage", "doctor", "vomiting", "WhatsApp", "Patients", "diarrhea", "rejection", "infections", "500mg dose", "combination", "information", "sterisonline", "proliferation", "B lymphocytes", "abdominal pain", "pregnant women", "immune response", "developing fetus", "other medications", "liver transplants", "other complications", "healthcare provider", "Common side effects", "organ transplantation", "Mycophenolate mofetil", "immunosuppressive drug", "Mycoplasm M 500 therapy", "healthcare professional", "other immunosuppressants", "immunosuppressive effects", "potential adverse effects", "optimal therapeutic outcomes", "gastrointestinal disturbances", "comprehensive transplant treatment regimen" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1472, "imageuri": "https://productimages.withfloats.com/actual/6661a57fdd39d2ccddbc3bb9.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661a57fdd39d2ccddbc3bb9.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:03:09.216Z", "updatedon": "2026-03-12T08:00:39.14Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mycophenolate-mofetil-500mg/1472", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MYCOPLASM M 500", "category": "NEPHROLOGYRANGE", "tags": [ "MYCOPLASM M 500", "Mycophenolate mofetil (500mg)", "Mycophenolate mofetil 500 mg tablet", "Mycophenolate mofetil 500 mg price", "Mycophenolate mofetil 500 mg dosage", "Mycophenolate mofetil uses", "Mycophenolate mofetil side effects", "mycophenolate mofetil 500mg tablet uses", "mycophenolate mofetil 500mg dosage for kidney transplant", "mycophenolate mofetil 500mg for autoimmune disease" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6630b5c94793c41fd8f762b8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ulipristal 5mg", "description": "ULIPSTALL 5 \nULIPSTALL 5 Ulipristal Acetate Tablets 5mg serves as a selective progesterone receptor modulator (SPRM) designed for adult women managing moderate to severe uterine fibroid symptoms before menopause. This prescription medication from Steris Healthcare reduces fibroid volume, controls heavy menstrual bleeding, and alleviates associated pelvic pain, offering a non-surgical option for improved daily life. Each tablet delivers 5 mg of ulipristal acetate, which precisely targets progesterone pathways without affecting estrogen.​\n\nKey Uses of ULIPSTALL 5 Ulipristal Acetate Tablets 5 mg\nULIPSTALL 5 primarily treats uterine fibroids by shrinking their size and regulating excessive bleeding that leads to anemia. Healthcare providers prescribe it for women not planning pregnancy soon, often as a bridge to surgery or long-term management. It proves effective in reducing fibroid-related discomfort, enhancing hemoglobin levels, and restoring menstrual normalcy over treatment courses.​\n\nUterine Fibroid Management: Inhibits fibroid growth, leading to 20-50% volume reduction in many cases, easing pressure on the uterus.​\n\nHeavy Menstrual Bleeding Control: Decreases blood loss by up to 75%, preventing iron deficiency and fatigue.​\n\nPelvic Pain Relief: Alleviates bloating, cramping, and discomfort from enlarged fibroids.​\n\nPre-Surgical Preparation: Shrinks fibroids to simplify procedures like myomectomy or hysterectomy.​\n\nNote that ULIPSTALL 5 at 5 mg differs from the 30mg emergency contraceptive dose; it focuses solely on fibroid therapy under gynecological supervision.​\n\nKey Benefits of ULIPSTALL 5 Ulipristal Acetate Tablets 5 mg\nPatients experience rapid symptom relief, with many noticing lighter periods within weeks of starting ULIPSTALL 5. Its targeted action preserves fertility potential while delaying invasive interventions, boosting quality of life scores significantly in clinical use. The oral format ensures convenience over injectables or daily hormone therapies.​\n\nFibroid Shrinkage: Promotes apoptosis in fibroid cells, reducing size and symptoms without systemic hormone disruption.​\n\nAnemia Prevention: Corrects heavy bleeding-induced low hemoglobin, restoring energy and vitality.​\nImproved Daily Functioning: Lessens pain and bleeding, enabling better work, exercise, and intimacy.​\nRepeatable Treatment Cycles: Allows up to three-month courses with breaks, offering flexible long-term control.​\n\nMinimal Impact on Ovulation: Maintains cycle predictability post-treatment for family planning.​\n\nRegular monitoring enhances these outcomes, making ULIPSTALL 5 a cornerstone in modern fibroid care.​\n\nPotential Side Effects of ULIPSTALL 5\nULIPSTALL 5 remains well-tolerated in most users, with transient effects resolving after discontinuation. Liver function checks prove essential due to rare hepatic risks.​\nCommon Side Effects:\nHeadaches and hot flashes, affecting initial days.​\n\nAbdominal pain, nausea, or mild breast tenderness.​\n\nFatigue or menstrual spotting during therapy.​\n\nSerious Side Effects (Rare):\n\nLiver enzyme elevations requiring immediate tests.​\n\nEndometrial thickening (reversible) or severe allergic reactions like rash/swelling.​\n\nPersistent jaundice, unexplained bleeding, or intense pain demands urgent care.​\n\nAvoid in pregnancy, breastfeeding, or liver disease; report changes promptly.​\nDosage Guidelines and Precautions\nTake one ULIPSTALL 5 tablet (5 mg) daily at the same time, with or without food, for up to three months per cycle. Doctors may repeat after a drug-free interval based on ultrasounds and bloodwork. Use non-hormonal contraception during and for four weeks post-treatment.​\n\nPrecautions include avoiding CYP3A4 drugs like rifampicin (reduces efficacy) or ketoconazole (increases levels) and St. John’s Wort. Baseline and monthly liver tests ensure safety; discontinue if ALT exceeds three times normal.​\nConclusion: Transform Fibroid Management with ULIPSTALL 5 Ulipristal Acetate Tablets 5 mg\nULIPSTALL 5 Ulipristal Acetate Tablets 5mg empowers women with uterine fibroids through precise progesterone modulation, delivering substantial reductions in size, bleeding, and pain for enhanced well-being. Backed by its fibroid-shrinking prowess and manageable profile, it stands as a vital tool in gynecology from Steris Healthcare. Consult specialists to integrate it safely and reclaim control over reproductive health", "price": 1124.0, "discountamount": 338.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "5mg", "nausea", "tablet", "headache", "72 hours", "ovulation", "ULIPSTALL", "infections", "medication", "endometrium", "implantation", "abdominal pain", "Ulipristal tab", "menstrual changes", "ulipristal acetate", "Common side effects", "regular contraception", "contraceptive failure", "unprotected intercourse", "emergency contraception", "healthcare professional", "selective progesterone receptor modulator" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 880, "imageuri": "https://productimages.withfloats.com/actual/6630b5cb2a7a7008cb609a71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6630b5cb2a7a7008cb609a71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-30T09:11:37.328Z", "updatedon": "2026-04-08T10:30:27.245Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ulipristal-5mg/880", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ULIPSTALL 5", "category": "GYANECOLOGYRANGE", "tags": [ "ulipristal 5mg", "ulipristal 5mg tablet", "ulipristal 5mg cost", "ulipristal 5mg tablets", "ulipristal 5mg price in india", "ulipristal 5mg tab", "ulipristal 5mg tablet uses", "ulipristal 5 mg tablet side effects", "ulipristal 5 mg tablet price", "ulipristal acetate 5mg tablets price in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6a8c3838c90065ecdc86c757", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 4mg", "description": "SAMIGLUTIDE 4 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation contains 4 mg of semaglutide in 3 mL of solution, corresponding to approximately 1.34 mg/mL.\n\nSemaglutide is a GLP-1 receptor agonist that acts on physiological pathways involved in blood-glucose control, appetite, and gastrointestinal function. Its use should be based on the approved indication for the specific product and the advice of a qualified healthcare professional.\n\nProduct Overview\nProduct: SAMIGLUTIDE 4 MG\nActive substance: Semaglutide\nStrength: 4 mg/3 mL\nApproximate concentration: 1.34 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute: Subcutaneous administration, according to the applicable product instructions\n\nThe 4 mg/3 mL concentration is also associated with certain approved semaglutide products. However, this does not mean that their dosing schedules, indications, or administration instructions automatically apply to SAMIGLUTIDE 4 MG. The product-specific labeling should always be followed.\n\nWhat Is Semaglutide?\n\nSemaglutide is a medication belonging to the GLP-1 receptor agonist class. It acts similarly to the naturally occurring hormone glucagon-like peptide-1 (GLP-1).\n\nGLP-1 is involved in several processes related to metabolism. Its activity can influence insulin secretion, glucagon regulation, stomach emptying, and appetite. Depending on the particular semaglutide product and its regulatory authorization, semaglutide may be prescribed for conditions such as type 2 diabetes or chronic weight management in appropriately selected patients.\n\nBecause different semaglutide products can have different approved uses and formulations, treatment decisions should be based on the specific medicine being prescribed.\n\nSAMIGLUTIDE 4 MG Pre-Filled Pen\n\nSAMIGLUTIDE 4 MG is supplied in a pre-filled pen intended to provide a convenient format for subcutaneous administration.\n\nPre-filled devices can eliminate the need to draw medication from a conventional vial. Nevertheless, patients should be properly trained before using an injectable pen and should follow the instructions supplied with the specific product.\n\nThe pen should only be used according to its approved instructions, including the prescribed dose and administration schedule.\n\nStrength and Formulation\n\nEach stated 3 mL presentation contains 4 mg of semaglutide, giving a concentration of approximately 1.34 mg/mL.\n\nThe concentration of a medicine should not be confused with the amount delivered in every injection. The quantity administered depends on the design and dose settings of the particular pen.\n\nFor this reason, patients should not calculate or select their own dose based solely on the concentration printed on the package. The prescribed dose should come from the product's authorized instructions and the treating healthcare professional.\n\nHow Semaglutide Acts\n\nSemaglutide activates GLP-1 receptors, which are involved in the regulation of blood glucose and appetite.\n\nAmong its physiological effects, GLP-1 receptor activation can:\n\nSupport glucose-dependent insulin secretion.\nReduce inappropriate glucagon secretion when blood glucose is elevated.\nAffect gastrointestinal activity, including gastric emptying.\nInfluence appetite and food intake.\n\nThe overall response to treatment can vary between individuals and depends on factors such as the medical indication, prescribed dose, treatment duration, and other medicines being used.\n\nPotential Therapeutic Benefits\n\nWhen prescribed for an appropriate, authorized indication, semaglutide may form part of a broader treatment program.\n\nFor eligible individuals with type 2 diabetes, certain approved semaglutide medicines are used to improve glycemic control. Other approved semaglutide formulations have indications involving chronic weight management for qualifying patients.\n\nMedication should be considered alongside the broader treatment strategy recommended by a healthcare professional, which may include nutritional management, physical activity, glucose monitoring, and other appropriate interventions.\n\nPossible Side Effects\n\nLike other prescription medicines, semaglutide can cause unwanted effects.\n\nFrequently reported gastrointestinal reactions associated with semaglutide products include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort or pain\n\nNot every patient experiences these effects, and their severity can vary.\n\nSemaglutide products also have important safety considerations. Depending on the specific approved product, labeling includes warnings concerning conditions such as pancreatitis, gallbladder-related problems, severe gastrointestinal reactions, kidney problems associated with dehydration, and serious hypersensitivity reactions.\n\nPatients should provide their healthcare professional with a complete medical history before treatment begins.\n\nImportant Contraindications and Warnings\n\nCertain semaglutide products carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity to semaglutide or an applicable component is also an important contraindication.\n\nThe exact warnings and contraindications applicable to SAMIGLUTIDE 4 MG should be confirmed against its current authorized product information in the relevant country.\n\nPatients should seek professional medical advice if they develop concerning symptoms during treatment.\n\nCorrect Administration\n\nSAMIGLUTIDE 4 MG should be administered only according to the prescription and instructions applicable to the product.\n\nBefore using a pre-filled pen, patients should receive appropriate instruction regarding:\n\nDose selection\nInjection technique\nInjection sites\nPen operation\nStorage\nDisposal of used needles or injection equipment\n\nThe dose or frequency should never be changed independently.\n\nA pre-filled injection pen should not be shared with another person, even if a new needle is attached. Sharing injectable medication devices can create a risk of transmitting infections and is contrary to appropriate safe-use practices.\n\nStorage\n\nStorage requirements should be determined from the official SAMIGLUTIDE 4 MG packaging and product information supplied with the medicine.\n\nPatients should not rely on storage instructions from a different semaglutide brand because formulations, devices, and stability requirements can differ between products.\n\nUse by Healthcare Professionals\n\nHealthcare professionals should assess whether SAMIGLUTIDE 4 MG is appropriate for an individual patient by considering the relevant diagnosis, treatment objectives, medical history, contraindications, concurrent medicines, and applicable regulatory requirements.\n\nParticular attention should be given to the distinction between different semaglutide products. Although they contain the same active ingredient, products may differ in:\n\nApproved indications\nConcentration\nPen design\nDose increments\nAdministration schedules\nStorage conditions\nRegulatory labeling\n\nThe product-specific prescribing information should therefore be consulted before treatment is initiated or adjusted.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can provide a practical method of administering an injectable medicine. Compared with a conventional vial-and-syringe presentation, the device may reduce some preparation steps and can be convenient for patients who have been appropriately trained.\n\nConvenience, however, should not take precedence over product authenticity, regulatory approval, correct dosing, proper storage, and professional medical supervision.\n\nSAMIGLUTIDE 4 MG: Key Points\n\nSAMIGLUTIDE 4 MG is described as a semaglutide injection containing 4 mg in 3 mL, supplied in a pre-filled pen.\n\nThe most important considerations are:\n\nSemaglutide is a GLP-1 receptor agonist.\nThe stated formulation is 4 mg/3 mL (approximately 1.34 mg/mL).\nAdministration is by the subcutaneous route when prescribed for that route.\nThe appropriate dose and frequency must come from the product-specific instructions and prescription.\nDosing information from another semaglutide brand should not automatically be applied.\nPatients should be informed about possible adverse reactions and relevant contraindications.\nThe pen must not be shared between patients.\nStorage and handling should follow the official product information.\nTreatment should be supervised by an appropriately qualified healthcare professional.\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 4 MG?\n\nSAMIGLUTIDE 4 MG is a semaglutide-containing injectable formulation described as 4 mg/3 mL, supplied in a pre-filled pen. Its approved use depends on the regulatory authorization applicable to the product and market.\n\nWhat does 4 mg/3 mL mean?\n\nIt indicates that the stated 3 mL presentation contains a total of 4 mg of semaglutide, equivalent to approximately 1.34 mg of semaglutide per mL.\n\nThis concentration alone should not be used to determine an individual's injection dose.\n\nIs SAMIGLUTIDE 4 MG a prescription medicine?\n\nSemaglutide medicines are prescription products in many jurisdictions. SAMIGLUTIDE 4 MG should be used only in accordance with applicable regulations, authorized product information, and professional medical advice.\n\nHow is SAMIGLUTIDE 4 MG administered?\n\nThe product is described as a subcutaneous injection. However, the exact dose, injection frequency, and pen operation should be determined from the SAMIGLUTIDE 4 MG product information and the patient's prescription.\n\nCan SAMIGLUTIDE 4 MG be taken together with another semaglutide medicine?\n\nPatients should not combine semaglutide-containing medicines or switch between them without medical supervision. Some approved semaglutide labels specifically advise against combining their product with another semaglutide-containing medicine or another GLP-1 receptor agonist.\n\nCan the dose be changed without consulting a doctor?\n\nNo. Patients should not increase, decrease, or otherwise modify the prescribed dose or injection schedule without guidance from their healthcare professional.\n\nConclusion\n\nSAMIGLUTIDE 4 MG – Semaglutide Injection 4 mg/3 mL (approximately 1.34 mg/mL) Pre-Filled Pen is a semaglutide-based injectable formulation designed for subcutaneous use according to its applicable product instructions.\n\nBecause semaglutide products can vary substantially in their approved indications, concentrations, devices, and dosing regimens, information from another semaglutide product should not be assumed to apply to SAMIGLUTIDE 4 MG.\n\nFor appropriate and safe use, patients and healthcare professionals should rely on the current official product information, local regulatory authorization, and individualized medical advice. Any questions concerning suitability, dosing, interactions, contraindications, or adverse effects should be discussed with a qualified healthcare professional.", "price": 6600.0, "discountamount": 1980.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2497, "imageuri": "https://productimages.withfloats.com/actual/6a8c383c0e00e8a5dab0c9d5.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c383c0e00e8a5dab0c9d5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:25:28.659Z", "updatedon": "2026-08-24T12:25:28.659Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-4mg/2497", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 4 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a8c35e76d1f6b0cbc0e2e40", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 2 mg", "description": "SAMIGLUTIDE 2 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation is Semaglutide Injection 2 mg/3 mL (0.68 mg/mL). Semaglutide belongs to the GLP-1 receptor agonist class and is a prescription medicine that should be used only under the supervision of an appropriately qualified healthcare professional.\n\nSAMIGLUTIDE 2 MG Composition\n\nEach 3 mL pre-filled pen is stated to contain:\n\nActive substance: Semaglutide\nStrength: 2 mg/3 mL\nConcentration: 0.68 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute of administration: Subcutaneous, according to the applicable product instructions\n\nSemaglutide acts on GLP-1 receptors, which are involved in blood-glucose regulation and appetite control. The approved uses, dosage regimen and strength available can differ according to the specific product and the regulations of the country in which it is supplied.\n\nWhat Is Semaglutide?\n\nSemaglutide is a synthetic peptide that mimics the activity of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). By activating GLP-1 receptors, it can influence several physiological processes, including glucose-dependent insulin release, glucagon secretion, gastric emptying and appetite.\n\nThe appropriate dose and treatment schedule depend on the individual patient and the particular semaglutide formulation. Patients should follow their healthcare professional's instructions and should not alter the prescribed regimen independently.\n\nSAMIGLUTIDE 2 MG Pre-Filled Pen\n\nSAMIGLUTIDE 2 MG is presented as a pre-filled injection pen intended to provide a convenient method of administration when the medicine has been prescribed.\n\nSince semaglutide products can differ in concentration, pen design and dose-delivery mechanism, users should carefully verify the product label and prescribed dose before each administration. Particular care is important with injectable semaglutide products because differences in concentration or measurement methods can result in medication errors.\n\nPotential Medical Uses\n\nSemaglutide may be used for particular medical conditions depending on the formulation, regulatory approval and prescribing information applicable to the product.\n\nCertain approved semaglutide medicines are indicated for the treatment of type 2 diabetes, while other formulations have approved indications involving chronic weight management in eligible patients. Some products may also have additional approved indications for reducing specific cardiovascular risks.\n\nThe fact that semaglutide can be used for weight management does not mean that every semaglutide product is approved for that purpose. The authorization and labeling of SAMIGLUTIDE should therefore be confirmed from current official product documentation.\n\nHow Semaglutide Works\n\nSemaglutide activates GLP-1 receptors in the body. Its effects can contribute to improved regulation of blood glucose and reduced appetite and food intake. Depending on the approved indication, it may be prescribed together with dietary, physical-activity or other appropriate medical measures.\n\nIndividual responses can vary. Medical follow-up helps healthcare professionals evaluate treatment response, tolerability and whether treatment should be continued or modified.\n\nDosage and Administration\n\nSAMIGLUTIDE 2 MG should be administered only in accordance with the prescription and the manufacturer's current instructions.\n\nThe amount of semaglutide contained in a pen should not automatically be interpreted as the amount to inject at one time. Different products may use different concentrations, dose settings and administration schedules.\n\nFor approved semaglutide products, treatment may involve gradual dose increases for certain indications. Patients should never increase the dose, inject more frequently or repeat a missed dose without receiving appropriate medical instructions.\n\nPossible Side Effects\n\nSemaglutide can cause adverse effects, particularly gastrointestinal symptoms. Frequently reported effects may include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort\nAbdominal pain\n\nMore serious reactions are also possible. Product information for semaglutide medicines includes warnings relating to conditions such as pancreatitis and gallbladder disorders, among other potential risks.\n\nPersistent, severe or unusual symptoms should be discussed promptly with a healthcare professional. Patients should review the complete prescribing information supplied with their particular product.\n\nImportant Safety Information\n\nSemaglutide is not appropriate for everyone. For example, certain approved semaglutide products in the United States carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and individuals with a serious hypersensitivity to semaglutide or an ingredient in the relevant product.\n\nThese precautions should not automatically be assumed to apply identically to every semaglutide product worldwide. The manufacturer's labeling and the regulatory requirements of the relevant country should always be consulted.\n\nPatients should inform their healthcare professional about their medical history and other medicines before starting treatment.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can make injectable treatment more convenient by providing the medication in a ready-to-use delivery device. When used according to the manufacturer's instructions, the pen may simplify administration and help patients maintain their prescribed treatment routine.\n\nPatients should nevertheless receive appropriate guidance regarding injection technique, storage, handling and disposal. The convenience of a pen does not eliminate the need for medical supervision.\n\nStorage and Handling\n\nSAMIGLUTIDE 2 MG should be stored exactly as stated on its packaging and official product information. Appropriate storage conditions are important for maintaining the quality and stability of the medicine.\n\nBefore use, check the expiry date and inspect the packaging and medicine according to the manufacturer's instructions. Do not use the product if the packaging is damaged or if the solution has an appearance that does not meet the stated product requirements.\n\nConclusion\n\nSAMIGLUTIDE 2 MG – Semaglutide Injection 2 mg/3 mL (0.68 mg/mL) is a semaglutide-based injectable formulation supplied in a pre-filled pen. Semaglutide is a GLP-1 receptor agonist with established medical applications for appropriately selected patients, depending on the specific product and its regulatory authorization.\n\nSafe use requires adherence to the prescribed dose and administration schedule. Patients should not independently change their dose or frequency and should seek professional advice if they experience concerning adverse effects.\n\nBecause formulations, indications, strengths and regulatory requirements can vary between products and countries, the current official package insert and applicable regulatory labeling should be used to verify product-specific information.\n\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 2 MG?\n\nSAMIGLUTIDE 2 MG is described as a semaglutide injection containing 2 mg of semaglutide in 3 mL, with a stated concentration of 0.68 mg/mL, supplied in a pre-filled pen.\n\nIs SAMIGLUTIDE 2 MG used for weight management?\n\nSemaglutide is included in certain approved medicines used for chronic weight management in eligible patients. However, the indication for a specific SAMIGLUTIDE product must be confirmed from its current regulatory approval and official labeling.\n\nHow frequently is SAMIGLUTIDE 2 MG injected?\n\nThe correct frequency depends on the specific product and the prescription issued by the healthcare professional. Patients should not determine the injection schedule based solely on the amount printed on the pen.\n\nCan SAMIGLUTIDE 2 MG be taken without medical supervision?\n\nNo. Semaglutide is a prescription medicine in many jurisdictions and should be obtained and used through legitimate, appropriately regulated healthcare channels.\n\nIs SAMIGLUTIDE the same as other branded semaglutide medicines?\n\nNot necessarily. Products containing semaglutide can differ in manufacturer, formulation, concentration, delivery device, regulatory approval and approved indications. A specific product should not be described as identical to an approved branded medicine unless that claim can be verified through reliable regulatory and product documentation.\n\nWhat should patients check before using the pen?\n\nPatients should verify the medicine name, strength, prescribed dose, expiry date, storage conditions and administration instructions. If there is any uncertainty about the dose or operation of the pen, they should consult their pharmacist, prescriber or another qualified healthcare professional rather than guessing.", "price": 5600.0, "discountamount": 1680.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2496, "imageuri": "https://productimages.withfloats.com/actual/6a8c35eaca4d2575d78e3716.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c35eaca4d2575d78e3716.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:15:35.873Z", "updatedon": "2026-08-24T12:15:35.873Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-2-mg/2496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 2 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }